

Trent M Woodruff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7842780/publications.pdf>

Version: 2024-02-01

215
papers

12,355
citations

23544

58
h-index

33869

99
g-index

244
all docs

244
docs citations

244
times ranked

15952
citing authors

#	ARTICLE	IF	CITATIONS
1	Monocyte CD14 and HLA-DR expression increases with disease duration and severity in amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 430-437.	1.1	4
2	Neuroinflammation in Huntingtonâ€™s. <i>Neuromethods</i> , 2022, , 215-233.	0.2	0
3	Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis. <i>Cancer Letters</i> , 2022, 529, 70-84.	3.2	51
4	Reduced Growth, Altered Gut Microbiome and Metabolite Profile, and Increased Chronic Kidney Disease Risk in Young Pigs Consuming a Diet Containing Highly Resistant Protein. <i>Frontiers in Nutrition</i> , 2022, 9, 816749.	1.6	7
5	In Vivo Pharmacodynamic Method to Assess Complement C5a Receptor Antagonist Efficacy. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 41-51.	2.5	5
6	Unexpected Off-Target Activities for Recombinant C5a in Human Macrophages. <i>Journal of Immunology</i> , 2022, 208, 133-142.	0.4	1
7	Complement drives circuit modulation in the adult brain. <i>Progress in Neurobiology</i> , 2022, 214, 102282.	2.8	4
8	Bothrops jararaca Snake Venom Inflammation Induced in Human Whole Blood: Role of the Complement System. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	5
9	Thrombin Differentially Modulates the Acute Inflammatory Response to <i>Escherichia coli</i> and <i>Staphylococcus aureus</i> in Human Whole Blood. <i>Journal of Immunology</i> , 2022, 208, 2771-2778.	0.4	1
10	A validated quantitative method for the assessment of neuroprotective barrier impairment in neurodegenerative disease models. <i>Journal of Neurochemistry</i> , 2021, 158, 807-817.	2.1	12
11	TDP-43 Puts the STING in ALS. <i>Trends in Neurosciences</i> , 2021, 44, 81-82.	4.2	14
12	An Immunoregulatory Role for Complement Receptors in Murine Models of Breast Cancer. <i>Antibodies</i> , 2021, 10, 2.	1.2	8
13	Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan. <i>Amino Acids</i> , 2021, 53, 143-147.	1.2	12
14	Processed foods drive intestinal barrier permeability and microvascular diseases. <i>Science Advances</i> , 2021, 7, .	4.7	80
15	C5a-C5aR1 Axis Activation Drives Envenomation Immunopathology by the Snake <i>Naja annulifera</i> . <i>Frontiers in Immunology</i> , 2021, 12, 652242.	2.2	8
16	Stimulating the Activity of NEP and ACE2: A Unique Approach to Prevent Dementia. <i>FASEB Journal</i> , 2021, 35, .	0.2	0
17	Glucose clearance and uptake is increased in the SOD1 ^{G93A} mouse model of amyotrophic lateral sclerosis through an insulin-independent mechanism. <i>FASEB Journal</i> , 2021, 35, e21707.	0.2	9
18	IMMU-09. MODULATING THE MYELOID POPULATION IN DIPG MODELS WITH ONCOLYTIC VIRUS AND COMPLEMENT INHIBITORS SHOWS THERAPEUTIC EFFICACY. <i>Neuro-Oncology</i> , 2021, 23, i28-i29.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Optimisation of a Microfluidic Method for the Delivery of a Small Peptide. <i>Pharmaceutics</i> , 2021, 13, 1505.	2.0	3
20	The complement cascade in the regulation of neuroinflammation, nociceptive sensitization, and pain. <i>Journal of Biological Chemistry</i> , 2021, 297, 101085.	1.6	29
21	Complement peptide receptors in GtoPdb v.2021.3. <i>IUPHAR/BPS Guide To Pharmacology CITE</i> , 2021, 2021, .	0.2	1
22	Intrinsic bias at non-canonical, β^2 -arrestin-coupled seven transmembrane receptors. <i>Molecular Cell</i> , 2021, 81, 4605-4621.e11.	4.5	69
23	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors. <i>British Journal of Pharmacology</i> , 2021, 178, S27-S156.	2.7	337
24	Anaphylatoxin receptor promiscuity for commonly used complement C5a peptide agonists. <i>International Immunopharmacology</i> , 2021, 100, 108074.	1.7	7
25	The emerging role of complement in neuromuscular disorders. <i>Seminars in Immunopathology</i> , 2021, 43, 817-828.	2.8	9
26	Air Bubbles Activate Complement and Trigger Hemostasis and C3-Dependent Cytokine Release Ex Vivo in Human Whole Blood. <i>Journal of Immunology</i> , 2021, 207, 2828-2840.	0.4	5
27	Sustained-release ketamine-loaded lipid-particulate system: in vivo assessment in mice. <i>Drug Delivery and Translational Research</i> , 2021, , 1.	3.0	0
28	Development of Potent and Selective Agonists for Complement C5a Receptor 1 with In Vivo Activity. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 16598-16608.	2.9	8
29	Mitochondrial C5aR1 activity in macrophages controls IL-1 β production underlying sterile inflammation. <i>Science Immunology</i> , 2021, 6, eabf2489.	5.6	50
30	Development of Synthetic Human and Mouse C5a: Application to Binding and Functional Assays <i>In Vitro</i> and <i>In Vivo</i> . <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1808-1817.	2.5	4
31	Complement C5a Induces Renal Injury in Diabetic Kidney Disease by Disrupting Mitochondrial Metabolic Agility. <i>Diabetes</i> , 2020, 69, 83-98.	0.3	48
32	The microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteins. <i>Glia</i> , 2020, 68, 407-421.	2.5	133
33	The Complement C5a-C5aR1 GPCR Axis in COVID-19 Therapeutics. <i>Trends in Immunology</i> , 2020, 41, 965-967.	2.9	44
34	Is the C3a receptor antagonist SB290157 a useful pharmacological tool?. <i>British Journal of Pharmacology</i> , 2020, 177, 5677-5678.	2.7	3
35	Absence of the C5a Receptor C5aR2 Worsens Ischemic Tissue Injury by Increasing C5aR1-Mediated Neutrophil Infiltration. <i>Journal of Immunology</i> , 2020, 205, 2834-2839.	0.4	17
36	Pharmacological characterisation of small molecule C5aR1 inhibitors in human cells reveals biased activities for signalling and function. <i>Biochemical Pharmacology</i> , 2020, 180, 114156.	2.0	47

#	ARTICLE	IF	CITATIONS
37	Absence of Receptor for Advanced Glycation End Product (RAGE) Reduces Inflammation and Extends Survival in the hSOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis. <i>Molecular Neurobiology</i> , 2020, 57, 4143-4155.	1.9	21
38	COVID-19: Complement, Coagulation, and Collateral Damage. <i>Journal of Immunology</i> , 2020, 205, 1488-1495.	0.4	127
39	Acetate protects against intestinal ischemia-reperfusion injury independent of its cognate free fatty acid 2 receptor. <i>FASEB Journal</i> , 2020, 34, 10418-10430.	0.2	12
40	Tissue-Type Plasminogen Activator and Tenecteplase-Mediated Increase in Blood Brain Barrier Permeability Involves Cell Intrinsic Complement. <i>Frontiers in Neurology</i> , 2020, 11, 577272.	1.1	3
41	The Peripheral Immune System and Amyotrophic Lateral Sclerosis. <i>Frontiers in Neurology</i> , 2020, 11, 279.	1.1	57
42	Complement: Bridging the innate and adaptive immune systems in sterile inflammation. <i>Journal of Leukocyte Biology</i> , 2020, 108, 339-351.	1.5	55
43	Editorial: The Role of Complement in Tumors. <i>Frontiers in Immunology</i> , 2020, 11, 139.	2.2	2
44	C5aR2 Activation Broadly Modulates the Signaling and Function of Primary Human Macrophages. <i>Journal of Immunology</i> , 2020, 205, 1102-1112.	0.4	37
45	Monocytes and neutrophils are associated with clinical features in amyotrophic lateral sclerosis. <i>Brain Communications</i> , 2020, 2, fcaa013.	1.5	26
46	Preclinical Pharmacokinetics of Complement C5a Receptor Antagonists PMX53 and PMX205 in Mice. <i>ACS Omega</i> , 2020, 5, 2345-2354.	1.6	64
47	Low Fouling Fluoropolymers for Bioconjugation and In Vivo Tracking. <i>Angewandte Chemie</i> , 2020, 132, 4759-4765.	1.6	22
48	Low Fouling Fluoropolymers for Bioconjugation and In Vivo Tracking. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 4729-4735.	7.2	40
49	Deep phenotyping detects a pathological CD4+ T-cell complosome signature in systemic sclerosis. <i>Cellular and Molecular Immunology</i> , 2020, 17, 1010-1013.	4.8	9
50	Sustained-release ketamine-loaded nanoparticles fabricated by sequential nanoprecipitation. <i>International Journal of Pharmaceutics</i> , 2020, 581, 119291.	2.6	36
51	The potential interplay between energy metabolism and innate complement activation in amyotrophic lateral sclerosis. <i>FASEB Journal</i> , 2020, 34, 7225-7233.	0.2	8
52	The α C3aR Antagonist SB290157 is a Partial C5aR2 Agonist. <i>Frontiers in Pharmacology</i> , 2020, 11, 591398.	1.6	11
53	Emerging Insights into the Structure and Function of Complement C5a Receptors. <i>Trends in Biochemical Sciences</i> , 2020, 45, 693-705.	3.7	57
54	Complement peptide receptors (version 2020.5) in the IUPHAR/BPS Guide to Pharmacology Database. <i>IUPHAR/BPS Guide To Pharmacology CITE</i> , 2020, 2020, .	0.2	0

#	ARTICLE	IF	CITATIONS
55	C5a receptors C5aR1 and C5aR2 mediate opposing pathologies in a mouse model of melanoma. <i>FASEB Journal</i> , 2019, 33, 11060-11071.	0.2	23
56	Distinct roles of the anaphylatoxin receptors C3aR, C5aR1 and C5aR2 in experimental meningococcal infections. <i>Virulence</i> , 2019, 10, 677-694.	1.8	23
57	Cholesterol Crystals Induce Coagulation Activation through Complement-Dependent Expression of Monocytic Tissue Factor. <i>Journal of Immunology</i> , 2019, 203, 853-863.	0.4	31
58	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors. <i>British Journal of Pharmacology</i> , 2019, 176, S21-S141.	2.7	519
59	Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody. <i>PLoS Biology</i> , 2019, 17, e3000323.	2.6	59
60	The Complement Receptor C5aR2: A Powerful Modulator of Innate and Adaptive Immunity. <i>Journal of Immunology</i> , 2019, 202, 3339-3348.	0.4	97
61	Gut microbiota in ALS: possible role in pathogenesis?. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 785-805.	1.4	30
62	Phagocytosis of live and dead <i>Escherichia coli</i> and <i>Staphylococcus aureus</i> in human whole blood is markedly reduced by combined inhibition of C5aR1 and CD14. <i>Molecular Immunology</i> , 2019, 112, 131-139.	1.0	8
63	Partial ligand-receptor engagement yields functional bias at the human complement receptor, C5aR1. <i>Journal of Biological Chemistry</i> , 2019, 294, 9416-9429.	1.6	34
64	Revisiting the role of the innate immune complement system in ALS. <i>Neurobiology of Disease</i> , 2019, 127, 223-232.	2.1	35
65	Deletion of Biliverdin Reductase A in Myeloid Cells Promotes Chemokine Expression and Chemotaxis in Part via a Complement C5aR1 Pathway. <i>Journal of Immunology</i> , 2019, 202, 2982-2990.	0.4	16
66	Therapeutic blockade of HMGB1 reduces early motor deficits, but not survival in the SOD1G93A mouse model of amyotrophic lateral sclerosis. <i>Journal of Neuroinflammation</i> , 2019, 16, 45.	3.1	21
67	Complement dysregulation in the central nervous system during development and disease. <i>Seminars in Immunology</i> , 2019, 45, 101340.	2.7	85
68	Commentary: Beyond C4: Analysis of the complement gene pathway shows enrichment for IQ in patients with psychotic disorders and healthy controls. <i>Frontiers in Immunology</i> , 2019, 10, 2853.	2.2	2
69	Complement component 5 does not interfere with physiological hemostasis but is essential for <i>Escherichia coli</i> -induced coagulation accompanied by Toll-like receptor 4. <i>Clinical and Experimental Immunology</i> , 2019, 196, 97-110.	1.1	6
70	Complement receptor C3aR1 controls neutrophil mobilization following spinal cord injury through physiological antagonism of CXCR2. <i>JCI Insight</i> , 2019, 4, .	2.3	58
71	Complement peptide receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. <i>IUPHAR/BPS Guide To Pharmacology CITE</i> , 2019, 2019, .	0.2	0
72	Complement in stem cells and development. <i>Seminars in Immunology</i> , 2018, 37, 74-84.	2.7	34

#	ARTICLE	IF	CITATIONS
73	Chronic Helminth Infection Perturbs the Gut-Brain Axis, Promotes Neuropathology, and Alters Behavior. <i>Journal of Infectious Diseases</i> , 2018, 218, 1511-1516.	1.9	6
74	<i>Staphylococcus aureus</i> -induced complement activation promotes tissue factor-mediated coagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 905-918.	1.9	25
75	Complement C5a Receptor 1 Exacerbates the Pathophysiology of <i>N.Âmeningitidis</i> Sepsis and Is a Potential Target for Disease Treatment. <i>MBio</i> , 2018, 9, .	1.8	30
76	T Cell Expression of C5a Receptor 2 Augments Murine Regulatory T Cell (TREG) Generation and TREG-Dependent Cardiac Allograft Survival. <i>Journal of Immunology</i> , 2018, 200, 2186-2198.	0.4	23
77	Role of complement anaphylatoxin receptors in a mouse model of acute burn-induced pain. <i>Molecular Immunology</i> , 2018, 94, 68-74.	1.0	4
78	Complement: The Emerging Architect of the Developing Brain. <i>Trends in Neurosciences</i> , 2018, 41, 373-384.	4.2	73
79	C5a receptor 1 promotes autoimmunity, neutrophil dysfunction and injury in experimental anti-myeloperoxidase glomerulonephritis. <i>Kidney International</i> , 2018, 93, 615-625.	2.6	64
80	Characterisation of small molecule ligands 4CMTB and 2CTAP as modulators of human FFA2 receptor signalling. <i>Scientific Reports</i> , 2018, 8, 17819.	1.6	6
81	C5aR1 is required for α -synuclein mediated NLRP3 inflammasome activation in microglia: Implications for Parkinson's disease. <i>Molecular Immunology</i> , 2018, 102, 229.	1.0	0
82	Inflammasome inhibition prevents α -synuclein pathology and dopaminergic neurodegeneration in mice. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	493
83	Inflammasomes in CNS Diseases. <i>Experientia Supplementum (2012)</i> , 2018, 108, 41-60.	0.5	31
84	Development and validation of a LC-MS/MS assay for pharmacokinetic studies of complement C5a receptor antagonists PMX53 and PMX205 in mice. <i>Scientific Reports</i> , 2018, 8, 8101.	1.6	21
85	Complement C3a receptor modulates embryonic neural progenitor cell proliferation and cognitive performance. <i>Molecular Immunology</i> , 2018, 101, 176-181.	1.0	30
86	C3aR1. , 2018, , 385-396.		0
87	C5aR2. , 2018, , 407-414.		0
88	New tricks for an ancient system: Physiological and pathological roles of complement in the CNS. <i>Molecular Immunology</i> , 2018, 102, 3-13.	1.0	85
89	Complement components are upregulated and correlate with disease progression in the TDP-43Q331K mouse model of amyotrophic lateral sclerosis. <i>Journal of Neuroinflammation</i> , 2018, 15, 171.	3.1	45
90	Systemic inhibition of the membrane attack complex impedes neuroinflammation in chronic relapsing experimental autoimmune encephalomyelitis. <i>Acta Neuropathologica Communications</i> , 2018, 6, 36.	2.4	39

#	ARTICLE	IF	CITATIONS
91	C5aR1 regulates T follicular helper differentiation and chronic graft-versus-host disease bronchiolitis obliterans. JCI Insight, 2018, 3, .	2.3	24
92	Properdin deficiency protects from 5-fluorouracil-induced small intestinal mucositis in a complement activation-independent, interleukin-10-dependent mechanism. Clinical and Experimental Immunology, 2017, 188, 36-44.	1.1	12
93	Pharmacological inhibition of complement C5a \times C5a ₁ receptor signalling ameliorates disease pathology in the hSOD1 ^{G93A} mouse model of amyotrophic lateral sclerosis. British Journal of Pharmacology, 2017, 174, 689-699.	2.7	79
94	The Alternative Receptor for Complement Component 5a, C5aR2, Conveys Neuroprotection in Traumatic Spinal Cord Injury. Journal of Neurotrauma, 2017, 34, 2075-2085.	1.7	34
95	Neuroinflammation as a therapeutic target in neurodegenerative diseases. , 2017, , 49-80.		7
96	Complement C5aR1 Signaling Promotes Polarization and Proliferation of Embryonic Neural Progenitor Cells through PKC η . Journal of Neuroscience, 2017, 37, 5395-5407.	1.7	63
97	Developmental activities of the complement pathway in migrating neurons. Nature Communications, 2017, 8, 15096.	5.8	83
98	Complement in the fundamental processes of the cell. Molecular Immunology, 2017, 84, 17-25.	1.0	47
99	Complement C5a-C5aR1 signalling drives skeletal muscle macrophage recruitment in the hSOD1G93A mouse model of amyotrophic lateral sclerosis. Skeletal Muscle, 2017, 7, 10.	1.9	45
100	New concepts on the therapeutic control of complement anaphylatoxin receptors. Molecular Immunology, 2017, 89, 36-43.	1.0	67
101	Noninvasive assessment of altered activity following restraint in mice using an automated physiological monitoring system. Stress, 2017, 20, 76-84.	0.8	6
102	THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview. British Journal of Pharmacology, 2017, 174, S1-S16.	2.7	269
103	The Ketone Body β -Hydroxybutyrate Does Not Inhibit Synuclein Mediated Inflammasome Activation in Microglia. Journal of NeuroImmune Pharmacology, 2017, 12, 568-574.	2.1	30
104	Specific inhibition of NLRP3 in chikungunya disease reveals a role for inflammasomes in alphavirus-induced inflammation. Nature Microbiology, 2017, 2, 1435-1445.	5.9	77
105	Monitoring C5aR2 Expression Using a Floxed tdTomato-C5aR2 Knock-In Mouse. Journal of Immunology, 2017, 199, 3234-3248.	0.4	44
106	Motor neuron disease proteins activate complement and generate C5a. Molecular Immunology, 2017, 89, 168.	1.0	0
107	Serpinc1/C1 Inhibitor Affects Cortical Development in a Cell Autonomous and Non-cell Autonomous Manner. Frontiers in Cellular Neuroscience, 2017, 11, 169.	1.8	32
108	Epha4-Fc Treatment Reduces Ischemia/Reperfusion-Induced Intestinal Injury by Inhibiting Vascular Permeability. Shock, 2016, 45, 184-191.	1.0	15

#	ARTICLE	IF	CITATIONS
109	Autoantibodies against homocysteinylated protein in a mouse model of folate deficiencyâ€”induced neural tube defects. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2016, 106, 201-207.	1.6	17
110	The Complement C3a Receptor Contributes to Melanoma Tumorigenesis by Inhibiting Neutrophil and CD4+ T Cell Responses. <i>Journal of Immunology</i> , 2016, 196, 4783-4792.	0.4	94
111	Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions. <i>Seminars in Immunology</i> , 2016, 28, 292-308.	2.7	66
112	The Complement System Component C5a Produces Thermal Hyperalgesia via Macrophage-to-Nociceptor Signaling That Requires NGF and TRPV1. <i>Journal of Neuroscience</i> , 2016, 36, 5055-5070.	1.7	64
113	Discovery of functionally selective C5aR2 ligands: novel modulators of C5a signalling. <i>Immunology and Cell Biology</i> , 2016, 94, 787-795.	1.0	68
114	A pathogenic role for the C5a receptor, C5aR2, in mouse models of Huntington's and Parkinson's disease. <i>Immunobiology</i> , 2016, 221, 1209.	0.8	2
115	Prokineticin-2 upregulation during neuronal injury mediates a compensatory protective response against dopaminergic neuronal degeneration. <i>Nature Communications</i> , 2016, 7, 12932.	5.8	75
116	Release of bioactive peptides from polyurethane films in vitro and in vivo: Effect of polymer composition. <i>Acta Biomaterialia</i> , 2016, 41, 264-272.	4.1	19
117	T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4 ⁺ T cells. <i>Science</i> , 2016, 352, aad1210.	6.0	395
118	C5a induces caspaseâ€”dependent apoptosis in brain vascular endothelial cells in experimental lupus. <i>Immunology</i> , 2016, 148, 407-419.	2.0	35
119	Motor deficits associated with Huntington's disease occur in the absence of striatal degeneration in BACHD transgenic mice. <i>Human Molecular Genetics</i> , 2016, 25, 1780-1791.	1.4	22
120	Contribution of the anaphylatoxin receptors, C3aR and C5aR, to the pathogenesis of pulmonary fibrosis. <i>FASEB Journal</i> , 2016, 30, 2336-2350.	0.2	53
121	Antiallodynic effects of alpha lipoic acid in an optimized RRâ€”EAE mouse model of MSâ€”neuropathic pain are accompanied by attenuation of upregulated BDNFâ€”TrkBâ€”ERK signaling in the dorsal horn of the spinal cord. <i>Pharmacology Research and Perspectives</i> , 2015, 3, e00137.	1.1	32
122	Placental lipase expression in pregnancies complicated by preeclampsia: a caseâ€”control study. <i>Reproductive Biology and Endocrinology</i> , 2015, 13, 100.	1.4	10
123	C5a alters bloodâ€”brain barrier integrity in a human <i>in vitro</i> model of systemic lupus erythematosus. <i>Immunology</i> , 2015, 146, 130-143.	2.0	56
124	A Commentary On: â€œNFâ€”B-Activated Astroglial Release of Complement C3 Compromises Neuronal Morphology and Function Associated with Alzheimer's Diseaseâ€” A cautionary note regarding C3aR. <i>Frontiers in Immunology</i> , 2015, 6, 220.	2.2	17
125	The Receptor for Advanced Glycation Endproducts Does Not Contribute to Pathology in a Mouse Mesenteric Ischemia/Reperfusion-Induced Injury Model. <i>Frontiers in Immunology</i> , 2015, 6, 614.	2.2	4
126	Absence of toll-like receptor 4 (TLR4) extends survival in the hSOD1G93A mouse model of amyotrophic lateral sclerosis. <i>Journal of Neuroinflammation</i> , 2015, 12, 90.	3.1	69

#	ARTICLE	IF	CITATIONS
127	The Complement Receptor C5aR Controls Acute Inflammation and Astrogliosis following Spinal Cord Injury. <i>Journal of Neuroscience</i> , 2015, 35, 6517-6531.	1.7	90
128	Properdin Provides Protection from <i>Citrobacter rodentium</i> -Induced Intestinal Inflammation in a C5a/IL-6-Dependent Manner. <i>Journal of Immunology</i> , 2015, 194, 3414-3421.	0.4	24
129	A novel anticonvulsant mechanism via inhibition of complement receptor C5ar1 in murine epilepsy models. <i>Neurobiology of Disease</i> , 2015, 76, 87-97.	2.1	55
130	Is the Complement Activation Product C3a a Proinflammatory Molecule? Re-evaluating the Evidence and the Myth. <i>Journal of Immunology</i> , 2015, 194, 3542-3548.	0.4	219
131	The Role of C5a Receptor Signaling in Endotoxin-Induced Miscarriage and Preterm Birth. <i>American Journal of Reproductive Immunology</i> , 2015, 74, 148-155.	1.2	4
132	Co-ordinated expression of innate immune molecules during mouse neurulation. <i>Molecular Immunology</i> , 2015, 68, 253-260.	1.0	19
133	Altered expression of metabolic proteins and adipokines in patients with amyotrophic lateral sclerosis. <i>Journal of the Neurological Sciences</i> , 2015, 357, 22-27.	0.3	70
134	Derivation of ligands for the complement C3a receptor from the C-terminus of C5a. <i>European Journal of Pharmacology</i> , 2014, 745, 176-181.	1.7	16
135	Leucocyte expression of complement C5a receptors exacerbates infarct size after myocardial reperfusion injury. <i>Cardiovascular Research</i> , 2014, 103, 521-529.	1.8	41
136	Insights into the mechanism of C5aR inhibition by PMX53 via implicit solvent molecular dynamics simulations and docking. <i>BMC Biophysics</i> , 2014, 7, 5.	4.4	21
137	Role for terminal complement activation in amyotrophic lateral sclerosis disease progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E3-4.	3.3	45
138	Increased Placental Expression of Fibroblast Growth Factor 21 in Gestational Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E591-E598.	1.8	39
139	Elevation of the terminal complement activation products C5a and C5b-9 in ALS patient blood. <i>Journal of Neuroimmunology</i> , 2014, 276, 213-218.	1.1	60
140	Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods. <i>Pharmacology Biochemistry and Behavior</i> , 2014, 126, 13-27.	1.3	34
141	Crosstalk between TGF β 21 and complement activation augments epithelial injury in pulmonary fibrosis. <i>FASEB Journal</i> , 2014, 28, 4223-4234.	0.2	76
142	Brief Report: Complement C5a Promotes Human Embryonic Stem Cell Pluripotency in the Absence of FGF2. <i>Stem Cells</i> , 2014, 32, 3278-3284.	1.4	47
143	Placental Lipases in Pregnancies Complicated by Gestational Diabetes Mellitus (GDM). <i>PLoS ONE</i> , 2014, 9, e104826.	1.1	33
144	Complement in Pregnancy: A Delicate Balance. <i>American Journal of Reproductive Immunology</i> , 2013, 69, 3-11.	1.2	68

#	ARTICLE	IF	CITATIONS
145	Complement factor C5a as mast cell activator mediates vascular remodelling in vein graft disease. <i>Cardiovascular Research</i> , 2013, 97, 311-320.	1.8	49
146	Elevated complement factor C5a in maternal and umbilical cord plasma in preeclampsia. <i>Journal of Reproductive Immunology</i> , 2013, 97, 211-216.	0.8	48
147	The C5a receptor antagonist PMX205 ameliorates experimentally induced colitis associated with increased IL-4 and IL-10. <i>British Journal of Pharmacology</i> , 2013, 168, 488-501.	2.7	45
148	A Small Molecule Angiotensin II Type 2 Receptor (AT ₂ R) Antagonist Produces Analgesia in a Rat Model of Neuropathic Pain by Inhibition of p38 Mitogen-Activated Protein Kinase (MAPK) and p44/p42 MAPK Activation in the Dorsal Root Ganglia. <i>Pain Medicine</i> , 2013, 14, 1557-1568.	0.9	66
149	Neutrophils—A Key Component of Ischemia-Reperfusion Injury. <i>Shock</i> , 2013, 40, 463-470.	1.0	178
150	C5L2: a controversial receptor of complement anaphylatoxin, C5a. <i>FASEB Journal</i> , 2013, 27, 855-864.	0.2	181
151	Neural tube defects, folate, and immune modulation. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2013, 97, 602-609.	1.6	37
152	C5a Receptor Signaling Prevents Folate Deficiency-Induced Neural Tube Defects in Mice. <i>Journal of Immunology</i> , 2013, 190, 3493-3499.	0.4	41
153	The receptor for complement component C3a mediates protection from intestinal ischemia-reperfusion injuries by inhibiting neutrophil mobilization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 9439-9444.	3.3	128
154	Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. <i>Journal of Neuroinflammation</i> , 2013, 10, 119.	3.1	76
155	Complement C5a Regulates Proinflammatory Mediators in Human Placenta. <i>Biology of Reproduction</i> , 2012, 86, 190.	1.2	22
156	Generation of complement component C5a by ischemic neurons promotes neuronal apoptosis. <i>FASEB Journal</i> , 2012, 26, 3680-3690.	0.2	86
157	Antagonizing C5aR Reduces T Cell-IL-10-Dependent Colitis in Pre-Clinical Models. <i>Inflammatory Bowel Diseases</i> , 2012, 18, S110.	0.9	0
158	De novo protein design of agonists and antagonists of C5a receptors. <i>Immunobiology</i> , 2012, 217, 1162-1163.	0.8	5
159	Complement activation in the injured central nervous system: another dual-edged sword?. <i>Journal of Neuroinflammation</i> , 2012, 9, 137.	3.1	108
160	Eph/Ephrin Signaling in Injury and Inflammation. <i>American Journal of Pathology</i> , 2012, 181, 1493-1503.	1.9	199
161	De Novo Peptide Design with C3a Receptor Agonist and Antagonist Activities: Theoretical Predictions and Experimental Validation. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 4159-4168.	2.9	31
162	Comparative efficacy of a secretory phospholipase A2 inhibitor with conventional anti-inflammatory agents in a rat model of antigen-induced arthritis. <i>Arthritis Research and Therapy</i> , 2011, 13, R42.	1.6	20

#	ARTICLE	IF	CITATIONS
163	Increased expression of C5a receptor (CD88) mRNA in canine mammary tumors. <i>Veterinary Immunology and Immunopathology</i> , 2011, 139, 50-56.	0.5	6
164	Inhibition of Inflammation and Fibrosis by a Complement C5a Receptor Antagonist in DOCA-Salt Hypertensive Rats. <i>Journal of Cardiovascular Pharmacology</i> , 2011, 58, 479-486.	0.8	33
165	Oral treatment with complement factor C5a receptor (CD88) antagonists inhibits experimental periodontitis in rats. <i>Journal of Periodontal Research</i> , 2011, 46, 643-647.	1.4	22
166	Inhibiting the C5a-C5a receptor axis. <i>Molecular Immunology</i> , 2011, 48, 1631-1642.	1.0	272
167	Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. <i>Molecular Neurodegeneration</i> , 2011, 6, 11.	4.4	431
168	Complement C5a inhibition reduces atherosclerosis in ApoE ^{-/-} mice. <i>FASEB Journal</i> , 2011, 25, 2447-2455.	0.2	76
169	The role of the ribosomal protein S19 C-terminus in Gi protein-dependent alternative activation of p38 MAP kinase via the C5a receptor in HMC-1 cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2010, 15, 966-981.	2.2	20
170	The Role of the Complement System and the Activation Fragment C5a in the Central Nervous System. <i>NeuroMolecular Medicine</i> , 2010, 12, 179-192.	1.8	136
171	Complement expression in mice throughout neural tube closure. <i>Molecular Immunology</i> , 2010, 47, 2251-2251.	1.0	2
172	Dysregulation of the complement system in neurodegenerative disease. <i>Molecular Immunology</i> , 2010, 47, 2270-2270.	1.0	0
173	The role of complement anaphylatoxin receptors in mesenteric ischemia/reperfusion-induced injury. <i>Molecular Immunology</i> , 2010, 47, 2270-2270.	1.0	0
174	Evidence that adiponectin receptor 1 activation exacerbates ischemic neuronal death. <i>Experimental & Translational Stroke Medicine</i> , 2010, 2, 15.	3.2	45
175	Microglial C5aR (CD88) expression correlates with amyloid β deposition in murine models of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2010, 113, 389-401.	2.1	76
176	Quantitative analysis of cellular inflammation after traumatic spinal cord injury: evidence for a multiphasic inflammatory response in the acute to chronic environment. <i>Brain</i> , 2010, 133, 433-447.	3.7	497
177	C5aR protects against folate-deficiency induced neural tube defects in mice. <i>Molecular Immunology</i> , 2010, 47, 2254-2254.	1.0	1
178	Pivotal role for beta-1 integrin in neurovascular remodelling after ischemic stroke. <i>Experimental Neurology</i> , 2010, 221, 107-114.	2.0	24
179	Treatment with a C5aR Antagonist Decreases Pathology and Enhances Behavioral Performance in Murine Models of Alzheimer's Disease. <i>Journal of Immunology</i> , 2009, 183, 1375-1383.	0.4	229
180	TOLL-LIKE RECEPTORS IN ISCHEMIA-REPERFUSION INJURY. <i>Shock</i> , 2009, 32, 4-16.	1.0	264

#	ARTICLE	IF	CITATIONS
181	Dendritic Cell Function in Allostimulation Is Modulated by C5aR Signaling. <i>Journal of Immunology</i> , 2009, 183, 6058-6068.	0.4	106
182	Complement component 5a (C5a). <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 2114-2117.	1.2	149
183	Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. <i>Neuroscience</i> , 2009, 158, 1074-1089.	1.1	110
184	Complement factors C3a and C5a have distinct hemodynamic effects in the rat. <i>International Immunopharmacology</i> , 2009, 9, 800-806.	1.7	17
185	The C5a anaphylatoxin receptor CD88 is expressed in presynaptic terminals of hippocampal mossy fibres. <i>Journal of Neuroinflammation</i> , 2009, 6, 34.	3.1	17
186	Role of complement C5a in mechanical inflammatory hypernociception: potential use of C5a receptor antagonists to control inflammatory pain. <i>British Journal of Pharmacology</i> , 2008, 153, 1043-1053.	2.7	66
187	Pharmacokinetics of a C5a receptor antagonist in the rat after different sites of enteral administration. <i>European Journal of Pharmaceutical Sciences</i> , 2008, 33, 390-398.	1.9	22
188	The receptor for complement anaphylatoxin C5a protects against the development of airway hyperresponsiveness in allergic asthma by inhibiting cysteinyl leukotriene pathway. <i>Molecular Immunology</i> , 2008, 45, 4109-4110.	1.0	0
189	The role of C5a in reproductive impairment in the mouse and human. <i>Molecular Immunology</i> , 2008, 45, 4150.	1.0	0
190	Protective effects of C5a receptor antagonism in a mouse model of atherosclerosis. <i>Molecular Immunology</i> , 2008, 45, 4151.	1.0	0
191	Targeting ischemic brain injury with intravenous immunoglobulin. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 19-29.	1.5	33
192	The Complement Factor C5a Contributes to Pathology in a Rat Model of Amyotrophic Lateral Sclerosis. <i>Journal of Immunology</i> , 2008, 181, 8727-8734.	0.4	136
193	Role of Complement in Motor Neuron Disease: Animal Models and Therapeutic Potential of Complement Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2008, , 136-151.	0.8	11
194	Role of complement in motor neuron disease: animal models and therapeutic potential of complement inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2008, 632, 143-58.	0.8	27
195	The Role of the N-terminal Domain of the Complement Fragment Receptor C5L2 in Ligand Binding. <i>Journal of Biological Chemistry</i> , 2007, 282, 3664-3671.	1.6	46
196	Complement mediators in ischemia/reperfusion injury. <i>Clinica Chimica Acta</i> , 2006, 374, 33-45.	0.5	118
197	Complement inhibitors selectively attenuate injury following administration of cobra venom factor to rats. <i>International Immunopharmacology</i> , 2006, 6, 1224-1232.	1.7	30
198	Recent developments in C5/C5a inhibitors. <i>Expert Opinion on Therapeutic Patents</i> , 2006, 16, 445-458.	2.4	11

#	ARTICLE	IF	CITATIONS
199	Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB Journal, 2006, 20, 1407-1417.	0.2	129
200	Transdermal Pharmacology of Small Molecule Cyclic C5a Antagonists. , 2006, 586, 329-345.		8
201	Complement factor 5a as a therapeutic target. Drugs of the Future, 2006, 31, 325.	0.0	8
202	Increased Potency of a Novel Complement Factor 5a Receptor Antagonist in a Rat Model of Inflammatory Bowel Disease. Journal of Pharmacology and Experimental Therapeutics, 2005, 314, 811-817.	1.3	66
203	Comparative Agonist/Antagonist Responses in Mutant Human C5a Receptors Define the Ligand Binding Site. Journal of Biological Chemistry, 2005, 280, 17831-17840.	1.6	47
204	A potent and selective inhibitor of group IIa secretory phospholipase A2 protects rats from TNBS-induced colitis. International Immunopharmacology, 2005, 5, 883-892.	1.7	32
205	Potent Cyclic Antagonists of the Complement C5a Receptor on Human Polymorphonuclear Leukocytes. Relationships between Structures and Activity. Molecular Pharmacology, 2004, 65, 868-879.	1.0	100
206	Protective effects of a potent c5a receptor antagonist on experimental acute limb ischemia-reperfusion in rats. Journal of Surgical Research, 2004, 116, 81-90.	0.8	74
207	Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats. Journal of Hepatology, 2004, 40, 934-941.	1.8	68
208	THE ROLE OF THE COMPLEMENT SYSTEM IN ISCHEMIA-REPERFUSION INJURY. Shock, 2004, 21, 401-409.	1.0	281
209	A Potent Human C5a Receptor Antagonist Protects against Disease Pathology in a Rat Model of Inflammatory Bowel Disease. Journal of Immunology, 2003, 171, 5514-5520.	0.4	109
210	Protective Effect of a New C5a Receptor Antagonist against Ischemia-Induced Reperfusion Injury in the Rat Small Intestine. Journal of Surgical Research, 2002, 103, 260-267.	0.8	88
211	Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat. Arthritis and Rheumatism, 2002, 46, 2476-2485.	6.7	111
212	Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytes. Inflammation, 2001, 25, 171-177.	1.7	48
213	Characterization of the extracellular loop of the human C5a receptor 1. Abbreviations: C5aR, human complement fragment 5a receptor; WT, wild-type; G105D, C5aR mutated to aspartate at glycine105; P103Y, C5aR mutated to tyrosine at proline105; P103Y/G105D, C5aR containing both substitutions; C5adR74, des arginated C5a; F-[OPchaWR], phenylalanine [l-ornithine-proline-d-cyclohexylalanine-tryptophan-arginine]; MeFKPchaWr, N-methyl-L-phenylalanine-lysine-proline-d-cyclohexylalanine. Biochemical Pharmacology, 2001, 61, 1671-1678.	2.0	13
214	A New Small Molecule C5a Receptor Antagonist Inhibits the Reverse-Passive Arthus Reaction and Endotoxic Shock in Rats. Journal of Immunology, 2000, 164, 6560-6565.	0.4	103
215	Innate Immunity in ALS. , 0, , .		0